Guardant360® Liquid the first and only
The ultimate power behind cancer testing.
Guardant360® Liquid is now powered by Guardant Infinity™ — the first and only commercially available platform that unlocks both epigenomics and genomics to transform precision oncology.
Overview
Key features for Guardant360® Liquid
For patients with advanced-stagecancer
at diagnosis or progression.
740+ genes
with variants detected at as low as 0.001% MAF.*2 Including HRR genes, NTRK fusions, MSI & TMB
Tumour Fraction
based on methylation to accurately quantify disease burden.*2
7-day
turnaround time for fast treatment decisions.†3
Biomarker Panel
Guardant360® Liquid is guideline-complete for genomic biomarkers across advanced solid tumours.§2,4-7
| Covered guideline-recommended biomarkers for common cancer types: | |
|---|---|
| Lung | ALK, BRAF, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, FGFR4, KRAS, MET, NRG1, NTRK1, NTRK2, NTRK3, RET, ROS1 |
| Breast | AKT1, BRCA1, BRCA2, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, PALB2, PIK3CA, PTEN, RET, MSI, TMB |
| Colorectal | BRAF, ERBB2, KRAS, NRAS, NTRK1, NTRK2, NTRK3, PIK3CA, POLD1, POLE, RET, MSI |
| Prostate | AR-V7, ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MLH1, MRE11, NBN, PALB2, PTEN, RAD51B, RAD51C, RAD51D, RAD54L, RB1, TP53, MSI, TMB |
Unfold the full panel to see
all 740+ genes covered.*2
Get results in as little as 7 days.
Comprehensive support
across the cancer continuum.
* The first and only commercially available liquid biopsy to deliver genomic and epigenomic insights from a single input.
† Median turnaround time from sample receipt to results.
§ For genomic biomarkers.
MAF = Mutant Allele Fraction; MSI = Microsatellite Instability; TMB = Tumor Mutation Burden; ctDNA = Circulating Tumor DNA;
HR = Hormone Receptor; HER2 = Human Epidermal Growth Factor Receptor 2; TNBC = Triple Negative Breast Cancer; IHC = Immunohistochemistry;
CUP = Cancer Of Unknown Primary.
Important note: Guardant360® Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA. Guardant Hereditary Cancer was developed as an LDT and is not cleared or approved by the US FDA.
References: 1. 1. Guardant Health data on file. December 12, 2025. Guardant Health, Inc. Redwood City, CA., 2. Guardant360® Liquid Assay Specifications. October 14, 2024. Guardant Health, Inc. Redwood City, CA. 3. Guardant Health data on file. September 27, 2024. Guardant Health, Inc. Redwood City, CA. 4. Riely GJ, Wood DE, Ettinger DS, et al. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 5.2024, NCCN clinical practice guidelines in oncology. Accessed June 1, 2024. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf 5. Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines® Insights: Breast Cancer, Version 2.2024, NCCN clinical practice guidelines in oncology. Accessed June 1, 2024. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf 6. Benson AB, Venook AP, Adam M, et al. NCCN Guidelines® Insights: Colon Cancer, Version 3.2024, NCCN clinical practice guidelines in oncology. Accessed June 1, 2024. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf 7. Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines® Insights: Prostate Cancer, Version 4.2024, NCCN clinical practice guidelines in oncology. Accessed June 1, 2024. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf